Fluidigm to Participate in UBS Genomics 2.0 and MedTech Innovations Summit
August 09 2021 - 11:14AM
Fluidigm Corporation (Nasdaq:FLDM), an innovative
biotechnology tools provider with a vision to improve life through
comprehensive health insight, today announced that company
management will participate in the following investor event:
UBS Genomics 2.0 and MedTech Innovations
SummitWednesday, August 11, 2021Laguna Beach, CaliforniaPanel
presentation at 8:00 p.m. ET, 5:00 p.m. PT
The panel presentation includes a Fluidigm Imaging Mass
Cytometry™ customer discussing spatial imaging. Chris Linthwaite,
President and CEO, and Vikram Jog, Chief Financial Officer, will
also participate in investor meetings.
About Fluidigm Fluidigm (Nasdaq:FLDM)
focuses on the most pressing needs in translational and clinical
research, including cancer, immunology, and immunotherapy. Using
proprietary CyTOF® and microfluidics technologies, we develop,
manufacture, and market multi-omic solutions to drive meaningful
insights in health and disease, identify biomarkers to inform
decisions, and accelerate the development of more effective
therapies. Our customers are leading academic, government,
pharmaceutical, biotechnology, plant and animal research, and
clinical laboratories worldwide. Together with them, we strive to
increase the quality of life for all. For more information,
visit fluidigm.com.Fluidigm, the Fluidigm logo,
Advanta, and CyTOF are trademarks and/or registered trademarks
of Fluidigm Corporation in the United
States and/or other countries. All other trademarks are
the sole property of their respective owners. The Advanta™ Dx
SARS-CoV-2 RT-PCR Assay is for In Vitro Diagnostic Use. It is for
Use under Emergency Use Authorization Only. Rx Only. Other
Fluidigm products are provided for Research Use Only. Not for
use in diagnostic procedures.
Available Information We use our website
(fluidigm.com), investor site (investors.fluidigm.com), corporate
Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm),
and LinkedIn page (linkedin.com/company/fluidigm-corporation) as
channels of distribution of information about our products, our
planned financial and other announcements, our attendance at
upcoming investor and industry conferences, and other matters. Such
information may be deemed material information, and we may use
these channels to comply with our disclosure obligations under
Regulation FD. Therefore, investors should monitor our website and
our social media accounts in addition to following our press
releases, SEC filings, public conference calls, and
webcasts.
Contacts:
Investors:Peter DeNardo415 389
6400IR@fluidigm.com
Media:Mark SpearmanSenior Director, Corporate
Communications650 243 6621mark.spearman@fluidigm.com
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fluidigm (NASDAQ:FLDM)
Historical Stock Chart
From Apr 2023 to Apr 2024